A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSS-OVER STUDY FOR EVALUATION OF THE EFFICIENCY AND SAFETY OF TIOTROPIUM INHALATION SOLUTION (5 µG) VIA RESPIMAT® INHALER once a day for 24 weeks for children (6 to 12 years) with bronchopulmonary dysplasia
Latest Information Update: 07 May 2024
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Bronchopulmonary dysplasia
- Focus Therapeutic Use
- Acronyms TRIBOR
- 05 May 2024 Status changed from recruiting to discontinued.
- 12 Sep 2023 Protocol has been amended to change the phase of the trial from III to II and also change in patient number.
- 12 Sep 2023 Planned number of patients changed from 68 to 26.